File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Targeting YAP and Hippo signaling pathway in liver cancer

TitleTargeting YAP and Hippo signaling pathway in liver cancer
Authors
KeywordsHippo pathway
Liver cancer
Molecular therapeutics
YAP oncogene
Issue Date2010
PublisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/ett
Citation
Expert Opinion On Therapeutic Targets, 2010, v. 14 n. 8, p. 855-868 How to Cite?
AbstractImportance of the field: The Hippo signaling pathway plays pivotal roles in controlling both cell growth and organ size, emerging as a new paradigm in tumor suppression. Yes-associated protein (YAP) functions as a potent transcription co-activator and is a major downstream target tightly regulated by the Hippo pathway. Inactivation of the Hippo signaling induces YAP-mediated activation of various target genes that functionally causes cellular proliferation and outgrowth of organ size. Recently, YAP has been implicated as a bona fide oncogene in solid tumors, but little is known about its exact molecular mechanism in carcinogenesis. Areas covered in this review: We discuss the latest important findings in the Hippo signaling pathway and the possible means of developing potential cancer therapeutics by targeting multiple sites along the Hippo pathway. What the reader will gain: An overview of the emerging roles of YAP and Hippo signaling in oncogenesis and the possible ways of developing cancer therapies against the pathway components, downstream targets or interconnected pathways. Take home message: YAP is a key oncogenic driver in liver carcinogenesis and deregulation of the Hippo pathway causes tumor formation and malignancy. Targeting YAP and cognate downstream signaling targets may have clinical utility in cancer therapies. © 2010 Informa UK Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/129393
ISSN
2015 Impact Factor: 4.798
2015 SCImago Journal Rankings: 2.025
ISI Accession Number ID
Funding AgencyGrant Number
Research Grants of Hong KongGRF 771607 M
National University Health System of Singapore
University of Hong Kong
Funding Information:

This work is supported by a grant (GRF 771607 M) from the Research Grants of Hong Kong and a start-up fund from the National University Health System of Singapore to J Luk.

References

 

DC FieldValueLanguage
dc.contributor.authorLiu, AMen_HK
dc.contributor.authorXu, MZen_HK
dc.contributor.authorChen, Jen_HK
dc.contributor.authorPoon, RTen_HK
dc.contributor.authorLuk, JMen_HK
dc.date.accessioned2010-12-23T08:36:43Z-
dc.date.available2010-12-23T08:36:43Z-
dc.date.issued2010en_HK
dc.identifier.citationExpert Opinion On Therapeutic Targets, 2010, v. 14 n. 8, p. 855-868en_HK
dc.identifier.issn1472-8222en_HK
dc.identifier.urihttp://hdl.handle.net/10722/129393-
dc.description.abstractImportance of the field: The Hippo signaling pathway plays pivotal roles in controlling both cell growth and organ size, emerging as a new paradigm in tumor suppression. Yes-associated protein (YAP) functions as a potent transcription co-activator and is a major downstream target tightly regulated by the Hippo pathway. Inactivation of the Hippo signaling induces YAP-mediated activation of various target genes that functionally causes cellular proliferation and outgrowth of organ size. Recently, YAP has been implicated as a bona fide oncogene in solid tumors, but little is known about its exact molecular mechanism in carcinogenesis. Areas covered in this review: We discuss the latest important findings in the Hippo signaling pathway and the possible means of developing potential cancer therapeutics by targeting multiple sites along the Hippo pathway. What the reader will gain: An overview of the emerging roles of YAP and Hippo signaling in oncogenesis and the possible ways of developing cancer therapies against the pathway components, downstream targets or interconnected pathways. Take home message: YAP is a key oncogenic driver in liver carcinogenesis and deregulation of the Hippo pathway causes tumor formation and malignancy. Targeting YAP and cognate downstream signaling targets may have clinical utility in cancer therapies. © 2010 Informa UK Ltd.en_HK
dc.languageengen_US
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/etten_HK
dc.relation.ispartofExpert Opinion on Therapeutic Targetsen_HK
dc.rightsExpert Opinion on Therapeutic Targets. Copyright © Informa Healthcare.-
dc.subjectHippo pathwayen_HK
dc.subjectLiver canceren_HK
dc.subjectMolecular therapeuticsen_HK
dc.subjectYAP oncogeneen_HK
dc.subject.meshAdaptor Proteins, Signal Transducing - genetics - metabolism-
dc.subject.meshLiver Neoplasms - drug therapy - metabolism-
dc.subject.meshPhosphoproteins - genetics - metabolism-
dc.subject.meshSignal Transduction-
dc.titleTargeting YAP and Hippo signaling pathway in liver canceren_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1472-8222&volume=14&issue=8&spage=855&epage=868&date=2010&atitle=Targeting+YAP+and+Hippo+signaling+pathway+in+liver+cancer-
dc.identifier.emailPoon, RT: poontp@hkucc.hku.hken_HK
dc.identifier.emailLuk, JM: jmluk@hkucc.hku.hken_HK
dc.identifier.authorityPoon, RT=rp00446en_HK
dc.identifier.authorityLuk, JM=rp00349en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1517/14728222.2010.499361en_HK
dc.identifier.pmid20545481-
dc.identifier.scopuseid_2-s2.0-77954770827en_HK
dc.identifier.hkuros176623en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77954770827&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume14en_HK
dc.identifier.issue8en_HK
dc.identifier.spage855en_HK
dc.identifier.epage868en_HK
dc.identifier.isiWOS:000280637000006-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridLiu, AM=36134439500en_HK
dc.identifier.scopusauthoridXu, MZ=24339881700en_HK
dc.identifier.scopusauthoridChen, J=36652298900en_HK
dc.identifier.scopusauthoridPoon, RT=7103097223en_HK
dc.identifier.scopusauthoridLuk, JM=7006777791en_HK
dc.identifier.citeulike7616145-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats